{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:19:23Z","timestamp":1790795963020,"version":"4.1.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Waning of protection against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) conferred by 2 doses of the BNT162b2 vaccine begins shortly after inoculation and becomes substantial within 4 months. With that, the impact of prior infection on incident SARS-CoV-2 reinfection is unclear. Therefore, we examined the long-term protection of naturally acquired immunity (protection conferred by previous infection) compared to vaccine-induced immunity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective observational study of 124 500 persons, compared 2 groups: (1) SARS-CoV-2-naive individuals who received a 2-dose regimen of the BioNTech\/Pfizer mRNA BNT162b2 vaccine, and (2) previously infected individuals who have not been vaccinated. Two multivariate logistic regression models were applied, evaluating four SARS-CoV-2-related outcomes\u2014infection, symptomatic disease (coronavirus disease 2019 [COVID-19]), hospitalization, and death\u2014between 1 June and 14 August 2021, when the Delta variant was dominant in Israel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SARS-CoV-2-naive vaccinees had a 13.06-fold (95% confidence interval [CI], 8.08\u201321.11) increased risk for breakthrough infection with the Delta variant compared to unvaccinated-previously-infected individuals, when the first event (infection or vaccination) occurred during January and February of 2021. The increased risk was significant for symptomatic disease as well. When allowing the infection to occur at any time between March 2020 and February 2021, evidence of waning naturally acquired immunity was demonstrated, although SARS-CoV-2 naive vaccinees still had a 5.96-fold (95% CI: 4.85\u20137.33) increased risk for breakthrough infection and a 7.13-fold (95% CI: 5.51\u20139.21) increased risk for symptomatic disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Naturally acquired immunity confers stronger protection against infection and symptomatic disease caused by the Delta variant of SARS-CoV-2, compared to the BNT162b2 2-dose vaccine-indued immunity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciac262","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T11:48:12Z","timestamp":1649159292000},"page":"e545-e551","source":"Crossref","is-referenced-by-count":115,"title":["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: A Retrospective Cohort Study"],"prefix":"10.1093","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9875-3550","authenticated-orcid":false,"given":"Sivan","family":"Gazit","sequence":"first","affiliation":[{"name":"Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services , Tel Aviv , Israel"},{"name":"Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roei","family":"Shlezinger","sequence":"additional","affiliation":[{"name":"Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services , Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galit","family":"Perez","sequence":"additional","affiliation":[{"name":"Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Lotan","sequence":"additional","affiliation":[{"name":"Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asaf","family":"Peretz","sequence":"additional","affiliation":[{"name":"Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services , Tel Aviv , Israel"},{"name":"Internal Medicine COVID-19 Ward, Samson Assuta Ashdod University Hospital , Ashdod Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Ben-Tov","sequence":"additional","affiliation":[{"name":"Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services , Tel Aviv , Israel"},{"name":"Sackler Faculty of Medicine, School of Public Health, Tel Aviv University , Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esma","family":"Herzel","sequence":"additional","affiliation":[{"name":"Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillel","family":"Alapi","sequence":"additional","affiliation":[{"name":"Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani","family":"Cohen","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, School of Public Health, Tel Aviv University , Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khitam","family":"Muhsen","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, School of Public Health, Tel Aviv University , Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Chodick","sequence":"additional","affiliation":[{"name":"Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services , Israel"},{"name":"Sackler Faculty of Medicine, School of Public Health, Tel Aviv University , Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Patalon","sequence":"additional","affiliation":[{"name":"Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services , Tel Aviv , Israel"},{"name":"Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,5]]},"reference":[{"key":"2022082503052433000_CIT0001","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/s41591-021-01432-4","article-title":"A correlate of protection for SARS-CoV-2 vaccines is urgently needed","volume":"27","author":"Krammer","year":"2021","journal-title":"Nat Med"},{"key":"2022082503052433000_CIT0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-26672-3","article-title":"Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine","volume":"12","author":"Mizrahi","year":"2021","journal-title":"Nat Commun"},{"key":"2022082503052433000_CIT0003","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1056\/NEJMoa2114114","article-title":"Waning of BNT162b2 vaccine protection against SARS-CoV-2 Infection in Qatar","volume":"385","author":"ChemaiteAlly","year":"2021","journal-title":"N Engl J Med"},{"key":"2022082503052433000_CIT0004","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 vaccine booster against Covid-19 in Israel","volume":"385","author":"Bar-On","year":"2021","journal-title":"N Engl J Med"},{"key":"2022082503052433000_CIT0005","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 Months","volume":"385","author":"Levin","year":"2021","journal-title":"N Engl J Med"},{"key":"2022082503052433000_CIT0006","first-page":"1","article-title":"Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2","volume":"2021","author":"Levine-Tiefenbrun","year":"2021","journal-title":"Nat Med"},{"key":"2022082503052433000_CIT0007","first-page":"1237","article-title":"Waning of SARS-CoV-2 booster viral-load reduction effectiveness","author":"Levine-Tiefenbrun","year":"2021","journal-title":"medRxiv"},{"key":"2022082503052433000_CIT0008","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.15585\/mmwr.mm7034e2","article-title":"Sustained effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 associated hospitalizations among adults \u2014 United States, March\u2013July 2021","volume":"70","author":"Tenforde","year":"2021","journal-title":"Morb Mortal Wkly Rep"},{"key":"2022082503052433000_CIT0009","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(21)00575-4","article-title":"Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study","volume":"397","author":"Hansen","year":"2021","journal-title":"Lancet"},{"key":"2022082503052433000_CIT0010","first-page":"4","article-title":"COVID-19 cases and hospitalizations by COVID-19 vaccination status and previous COVID-19 diagnosis \u2014 California and New York, May\u2013November 2021","volume":"71","author":"Le\u00f3n","year":"2022","journal-title":"Centers for Disease Control MMWR Office"},{"key":"2022082503052433000_CIT0011","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1473-3099(20)30783-0","article-title":"What reinfections mean for COVID-19","volume":"21","author":"Iwasaki","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2022082503052433000_CIT0012","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jinf.2020.08.011","article-title":"Setting the criteria for SARS-CoV-2 reinfection: six possible cases","volume":"82","author":"Tomassini","journal-title":"J Infect"},{"key":"2022082503052433000_CIT0013","year":"2020"},{"key":"2022082503052433000_CIT0014","author":"Perez","year":"2021"},{"key":"2022082503052433000_CIT0015","first-page":"533","article-title":"Antibody status and incidence of SARS-CoV-2 infection in health care workers","volume-title":"N Engl J Med","author":"Lumley","year":"2021"},{"key":"2022082503052433000_CIT0016","volume-title":"SARS-CoV-2 variants in analyzed sequences"},{"key":"2022082503052433000_CIT0017","first-page":"1","article-title":"Are Greenland, Ioannidis, and Poole opposed to the Cornfield conditions? A defence of the E-value","volume":"dyab218","author":"VanderWeele","year":"2021","journal-title":"Int J Epidemiol"},{"key":"2022082503052433000_CIT0018","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"Van Der Weele","year":"2017","journal-title":"Ann Intern Med"},{"key":"2022082503052433000_CIT0019","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/vaccines9020147","article-title":"SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond","volume":"9","author":"Bettini","year":"2021","journal-title":"Vaccines"},{"key":"2022082503052433000_CIT0020","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Leading Edge Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"2022082503052433000_CIT0021","first-page":"e240","article-title":"Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study","volume-title":"Lancet Microbe","author":"Chia","year":"2021"},{"key":"2022082503052433000_CIT0022","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41586-021-04060-7","article-title":"Antibody evolution after SARS-CoV-2 mRNA vaccination","volume":"600","author":"Cho","year":"2021","journal-title":"Nature"},{"key":"2022082503052433000_CIT0023","doi-asserted-by":"crossref","first-page":"100354","DOI":"10.1016\/j.xcrm.2021.100354","article-title":"Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells","volume":"2","author":"Cohen","year":"2021","journal-title":"Cell Reports Med"},{"key":"2022082503052433000_CIT0024","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/infdis\/jiab543","article-title":"Durability of SARS-CoV-2-specific T cell responses at 12-months post-infection","volume":"224","author":"Lu","year":"2021","journal-title":"The Journal of Infectious Diseases"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac262\/43691900\/ciac262.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/1\/e545\/45514316\/ciac262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/1\/e545\/45514316\/ciac262.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T23:09:06Z","timestamp":1661382546000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/75\/1\/e545\/6563799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,4,5]]},"published-print":{"date-parts":[[2022,8,24]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac262","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.08.24.21262415","asserted-by":"object"}]},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,4,5]]}}}